1. Proost JH. Comment on: "Challenges in individualizing drug dosage for intensive care unit patients". [letter]. Clin Pharmacokinet.
2. Jelliffe R. Challenges in individualizing drug dosage for intensive care unit patients: is augmented renal clearance what we really want to know? Some suggested management approaches and clinical software tools. Clin Pharmacokinet. 2016;55(8):897–905. doi: 10.1007/s40262-016-0369-4 .
3. D’Argenio D. Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharmacol. 1981;9:739–56.
4. Bayard D, Jelliffe R, Neely M. Bayes risk as an alternative to fisher information in determining experimental designs for nonparametric models [slides and abstracts]. Population Optimal Design of Experiments Conference, Lilly Laboratories, Erl Wood Manor, Windesham, Surrey, UK, June 15, 2013. http://www.maths.qmul.ac.uk/~bb/PODE/PODE2013_Slides/PODE2013_RogerJelliffe.pdf . Accessed 8 Dec 2016.
5. Jelliffe R, Bayard D, Neely M. MMopt—an optimal TDM protocol strategy based on Bayes risk and weighted Bayes risk [oral presentation]. In: 14th congress of the international Association for Therapeutic Drug Monitoring and Clinical Toxicology, 14 Oct 2015, Rotterdam.